Connective Therapeutics, Inc. Names Vice President of Corporate Development.PALO ALTO Palo Alto, city, California Palo Alto (păl`ō ăl`tō), city (1990 pop. 55,900), Santa Clara co., W Calif.; inc. 1894. Although primarily residential, Palo Alto has aerospace, electronics, and advanced research industries. , Calif.--(BUSINESS WIRE)--Sept. 5, 1995--Connective Therapeutics, Inc. announced today the appointment of Richard J. Hammel, Ph.D., to the newly-created position of vice president corporate development. Dr. Hammel, 52, was formerly vice president of business development at Matrix Pharmaceutical, Inc. where he developed the company's corporate partnering initiatives in both Europe and Japan and sales and marketing strategies for its late stage products. Prior to joining Matrix, Dr. Hammel held several positions at Glaxo, Inc. in Research Triangle Park Research Triangle Park, research, business, medical, and educational complex situated in central North Carolina. It has an area of 6,900 acres (2,795 hectares) and is 8 × 2 mi (13 × 3 km) in size. Named for the triangle formed by Duke Univ. , NC including director of new business development. At Glaxo, he was instrumental in the completion of a number of corporate partnering agreements with biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. such as Gilead, Amylin and ICOS. He holds a Ph.D. (1977) and a masters degree (1974) in pharmacy and health care administration and a bachelor's degree in pharmacy (1970) from the University of Minnesota (body, education) University of Minnesota - The home of Gopher. http://umn.edu/. Address: Minneapolis, Minnesota, USA. . "Rick joins Connective connective - An operator used in logic to combine two logical formulas. See first order logic. Therapeutics with a significant track record of building successful business and corporate development programs in both major pharmaceutical companies and emerging technology based organizations," said Thomas G. Wiggans, president and chief executive officer at Connective Therapeutics. "He brings extraordinary international experience and contacts within the pharmaceutical and health care industries. These assets are especially important to our company at this critical time as we expand our corporate partnering and accelerated commercialization activities. We are very pleased to have Dr. Hammel joining our management team," said Wiggans. Connective Therapeutics, founded in 1993, is a privately-held firm focused on the development of novel therapeutics for chronic connective tissue disorders. The company's therapeutic approaches are based on controlling cells that produce excessive or abnormal connective tissue, and on modulating the immune response immune response n. An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. directly associated with certain connective tissue diseases connective tissue disease Autoimmune disease, collagen-vascular disease Any of the diseases affecting connective tissues, with an autoimmune component, and immunologic/inflammatory defects Clinical Arthritis, connective tissue defects, endocarditis, myositis, . The company's investors include Kleiner, Perkins, Caufield and Byers; Sierra Ventures; Domain Associates; Biotechnology Investments, Ltd.; the Sprout Group; GIMV, Sofinnova and Lease Management Services. Genentech, Inc. is a stockholder in the company. CONTACT: Connective Therapeutics Inc. Thomas G. Wiggans, 415/843-2800 or StratiPoint Group, Inc. Mike Jackman, 415/388-3216 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion